Skip to main content
Log in

Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta

  • Original
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

We studied how interferon-beta (IFN-β) treatment of relapsing-remitting multiple sclerosis (MS) affects subgroups of natural killer cells (NK cells). Following IFN-β treatment, there was an expansion of CD56Bright NK-cells in the peripheral blood of MS patients, while at the same time the proportion of CD56Dim cells was diminished. In a control group, the proportion of CD56Bright NK-cells was significantly higher in secondary lymphoid tissues compared to the peripheral blood of the same individual. Our findings confirm that CD56Bright NK-cells preferably locate within the secondary lymphoid tissues, where they may interact with T cells and thereby contribute to the control of the disease activity in MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199:971–979

    Article  PubMed  CAS  Google Scholar 

  2. Takahashi K, Aranami T, Endoh M et al (2004) The regulatory role of natural killer cells in multiple sclerosis. Brain 127:1917–1927

    Article  PubMed  Google Scholar 

  3. Takahashi K, Miyake S, Kondo T et al (2001) Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 107:R23–R29

    Article  PubMed  CAS  Google Scholar 

  4. Infante-Duarte C, Weber A, Kratzschmar J et al (2005) Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 19:1902–1904

    PubMed  CAS  Google Scholar 

  5. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294

    Article  PubMed  CAS  Google Scholar 

  6. Yong VW (2002) Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59:802–808

    PubMed  CAS  Google Scholar 

  7. Perini P, Wadhwa M, Buttarello M et al (2000) Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients. J Neuroimmunol 105:91–95

    Article  PubMed  CAS  Google Scholar 

  8. Kastrukoff LF, Morgan NG, Zecchini D et al (1998) A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 86:123–133

    Article  PubMed  CAS  Google Scholar 

  9. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640

    Article  PubMed  CAS  Google Scholar 

  10. Li Z, Lim WK, Mahesh SP et al (2005) Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174:5187–5191

    PubMed  CAS  Google Scholar 

  11. Cooper MA, Fehniger TA, Turner SC et al (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97:3146–3151

    Article  PubMed  CAS  Google Scholar 

  12. Campbell JJ, Qin S, Unutmaz D et al (2001) Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166:6477–6482

    PubMed  CAS  Google Scholar 

  13. Fehniger TA, Cooper MA, Nuovo GJ et al (2003) CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101:3052–3057

    Article  PubMed  CAS  Google Scholar 

  14. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297–336

    Article  PubMed  CAS  Google Scholar 

  15. Dalbeth N, Callan MF (2002) A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 46:1763–1772

    Article  PubMed  Google Scholar 

  16. Bielekova B, Catalfamo M, Reichert-Scrivner S et al (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103:5941–5946

    Article  PubMed  CAS  Google Scholar 

  17. Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG (2002) The natural killer cell — friend or foe in autoimmune disease? Scand J Immunol 55:432–441

    Article  PubMed  CAS  Google Scholar 

  18. Morse RH, Seguin R, McCrea EL, Antel JP (2001) NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol 116:107–115

    Article  PubMed  CAS  Google Scholar 

  19. Shi FD, Takeda K, Akira S et al (2000) IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 165:3099–3104

    PubMed  CAS  Google Scholar 

  20. Traugott U, Raine CS (1984) Further lymphocyte characterization in the central nervous system in multiple sclerosis. Ann N Y Acad Sci 436:163–180

    Article  PubMed  CAS  Google Scholar 

  21. Matsumoto Y, Kohyama K, Aikawa Y et al (1998) Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol 28:1681–1688

    Article  PubMed  CAS  Google Scholar 

  22. Weber WE, Buurman WA, Vandermeeren MM et al (1987) Fine analysis of cytolytic and natural killer T lymphocytes in M. the CSF in multiple sclerosis and other neurologic diseases. Neurology 37:419–425

    PubMed  CAS  Google Scholar 

  23. Zhang B, Yamamura T, Kondo T et al (1997) Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 186:1677–1687

    Article  PubMed  CAS  Google Scholar 

  24. Smeltz RB, Wolf NA, Swanborg RH (1999) Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J Immunol 163:1390–1397

    PubMed  CAS  Google Scholar 

  25. Xu W, Fazekas G, Hara H, Tabira T (2005) Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 163:24–30

    Article  PubMed  CAS  Google Scholar 

  26. Huang D, Shi FD, Jung S et al (2006) The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 20:896–905

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. Airas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saraste, M., Irjala, H. & Airas, L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28, 121–126 (2007). https://doi.org/10.1007/s10072-007-0803-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-007-0803-3

Key words

Navigation